Score releases September 2011 U.S. online video rankings
comScore Inc (SCOR) $20.49 +0.55 Co released data from the comScore Video Metrix service showing that 182 million U.S. Internet users watched online video content in September for an average of 19.5 hours per viewer. The total U.S. Internet audience engaged in 39.8 billion video views. Google (GOOG) Sites, driven primarily by video viewing at more »
Nucor sees Q3 EPS below consensus: NUE, WMGI
Nucor Corporation (NUE) 34.10 : Co sees Q3 EPS of $0.45-0.55 vs $0.66 Capital IQ Consensus Estimate. “As we expected, our profitability has deteriorated in Q3 compared to Q2 but continues well ahead of 2010 levels. The recent deterioration reflects lower steel prices and metal margins, particularly for sheet mill products, due to new domestic more »
Apache: TAG enters into farmout agreement with Apache Corporation on New Zealand Acreage in the East Coast Basin: APA, ETRM
Apache (APA)101.77 : Apache has agreed to conduct a multi-phased exploration, appraisal and potential development program within TAG’s East Coast Basin exploration permits. The permits comprise in excess of one million prospective acres of onshore oil and gas opportunities. TAG currently holds a 100% working interest in the properties. Co has agreed to pay for more »
Rubicon Minerals sells its royalty on company’s Phoenix Gold Project for $23.2 million: RBY, OXM
Rubicon Minerals (AMEX: RBY) $4.26 +0.11 : Co announce that Franco-Nevada has purchased all of the right, title and interest of Dominion Goldfields (“DGC”) in the 2% net smelter returns royalty payable on that part of Rubicon’s Phoenix Gold Project in Red Lake, Ontario lying beneath the waters of Red Lake (i.e. excluding mining properties more »
Cardium Therapeutics reported that it has planed to reestablish compliance: CXM
Cardium Therapeutics Inc. (AMEX: CXM) $0.20 +3.65% reported that it had submitted a modified compliance plan designed to reestablish compliance with its exchange listing requirements in view of ongoing plans related to the acquisition of a nutraceutical business designed to expand the Company’s MedPodium product line. In a related matter, the Company announced the incorporation more »
QEP Resources announced new $1.5 billion revolving credit facility: QEP, SCVL
QEP Resources (NYSE: QEP) $33.38 -1.49 announced that it has entered into a new $1.5 billion, 5-year, unsecured revolving credit agreement with a group of 19 financial institutions. The credit facility replaces the $1.0 billion credit facility that was scheduled to mature in March of 2013. The new credit facility provides for borrowings at short-term more »
Avago reports earnings: AVGO, RENN, EEFT, GOOG, SANM
Avago Tech (AVGO $32.18 +2.92) reported third quarter GAAP earnings of $0.57 per share, $0.02 better than the Capital IQ GAAP consensus of $0.55, while revenues rose 9.6% year/year to $603 million versus the $592.8 million consensus. The company issued in-line guidance for the fourth quarter with revenues +2-5% year over year to approximately $615.1-633.2 more »
LDK Solar lowers its revenue, shipment, and gross margin guidance for 2011: LDK, WXS
LDK Solar Co. Ltd. (NYSE: LDK) $6.57 - 3.52% lowers issues downside guidance for Q2 (Jun), lowers Q2 (Jun) revs to $480-500 mln from $710-760 mln vs. $716.40 mln Capital IQ Consensus Estimate. With wafer shipments between 1.8 gigawatts (GW) and 2.0 GW, and gross margins between 15% and 20%. The co previously forecasted wafer shipments between 2.7 and more »
Pfizer announces European Medicine Agency acceptance of regulatory submissions for two cancer therapies: PFE, NYMX
Pfizer Inc. (NYSE: PFE) $18.50 +0.19 announced today that the European Medicines Agency has accepted co’s regulatory submissions for review of two investigational compounds – crizotinib, an oral first-in-class anaplastic lymphoma kinase inhibitor, for the treatment of patients with previously treated ALK-positive advanced non-small cell lung cancer, and bosutinib for the treatment of adult patients with more »
Adolor announced a positive result from its Phase 2 program: ADLR, HAR
Adolor Corporation (NASDAQ: ADLR) $2.11 -4.52% announced positive, statistically significant top line results from its two Phase 2 studies of ADL5945 in chronic non-cancer pain patients with opioid-induced constipation. ADL5945, a peripherally-acting mu opioid receptor antagonist, is an investigational drug being evaluated for the treatment of OIC as well as other associated gastrointestinal complications. Both more »